Ambassador programUse RoicAI for free

Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc.

CSII

CSIICardiovascular Systems, Inc. US flag

NASDAQ Global Select

20.00

USD

+0.03

- -

843.96MMarket Cap

Cardiovascular Systems, Inc.

CSII

(NASDAQ Global Select)

Recent

price

20.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Computerized Thermal Imaging, Inc. (COIB)
EMVision Medical Devices Ltd (EMV.AX)
Natus Medical Incorporated (NTUS)
Beijing Chunlizhengda Medical Instruments Co., Ltd. (1858.HK)
Neola Medical AB (publ) (NEOLA.ST)
Stryker Corporation (SYK)
Business: Cardiovascular Systems, Inc., which now operates as a wholly-owned subsidiary of Abbott Laboratories, previously functioned as a medical technology enterprise dedicated to advancing solutions for peripheral and coronary artery disease across global markets. This organization focused on developing advanced atherectomy systems designed to manage plaque accumulation within arterial vessels. The company's offerings included specialized systems for treating peripheral artery disease, featuring catheter-based platforms capable of addressing various plaque types, notably calcified plaque, in both above and below-the-knee arteries. These solutions aimed to overcome challenges associated with conventional surgical, catheter, and pharmacological interventions. Furthermore, their portfolio encompassed essential peripheral support components. For coronary artery disease, the firm provided orbital atherectomy systems, such as the Diamondback 360 Coronary OAS, specifically engineered to assist in stent delivery for individuals with severe calcified lesions who are suitable candidates for percutaneous transluminal coronary angioplasty or stenting. Ancillary products like guidewires, catheters, balloons, and embolic protection systems also complemented their core technologies. Cardiovascular Systems, Inc. also engaged in collaborative efforts, including a partnership with Chansu Vascular Technologies, LLC, to innovate new drug-coated balloons for peripheral and coronary applications. The company, initially named Shturman Cardiology Systems, Inc., adopted its current name in January 2003, having been established in 1989 and headquartered in St. Paul, Minnesota. Abbott completed its acquisition of Cardiovascular Systems, Inc. on April 27, 2023, integrating its innovative atherectomy technology into Abbott's broader vascular device portfolio.

Company News